Robert Wermers, MD, and Monica Richey, MSN, ANP-bc, provide management updates and guidelines for clinicians who are treating patients with osteoporosis and osteopenia in their session at the Practical...
Osteoarthritis is a common chronic and degenerative disease among adults. A group of experts estimated the disease’s burden spanning two decades and the projection of burden to 2050.
Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...
In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.
In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...
Researchers examined the efficacy and safety of a humanized monoclonal antibody for the treatment of active psoriatic arthritis in some patient populations.